Choroideremia

Koira Pharmaceuticals, in a new partnership with the Choroideremia Research Foundation, plans to accelerate its development of KIO-301, a treatment for the rare retinal disease choroideremia.

Genetic testing and counseling are advisable in family members of patients with choroideremia, particularly female members of childbearing age, according to a poster presented at the virtual Euretina congress.

Wize Pharma has entered into an exclusive license agreement to develop and commercialize products based on non-viral gene therapy technology from Copernicus Therapeutics, the company announced in a press release.